# Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

> **NCT03367546** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 5 (actual)

## Conditions studied

- Sickle Cell Disease
- Thalassemia
- High Risk Hematologic Disorders
- Cerebral Adrenoleukodystrophy
- Inherited Metabolic Disorders

## Interventions

- **PROCEDURE:** Blood and Marrow Transplant

## Key facts

- **NCT ID:** NCT03367546
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-02
- **Primary completion:** 2022-12-19
- **Final completion:** 2022-12-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study no longer needed
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367546, "Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03367546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*